Oct 25: Hyderabad-based Suven Life Sciences Ltd, a specialty biopharmaceutical company developing therapeutics in Central Nervous System diseases, on Thursday announced completion of enrollment of patients with Last-Patient-In Goal for its Phase 2 POC study of SUVN-502 for moderate Alzheimer’s disease.
According to the company, it expects to report the top-line data of this study by July/August 2019 time frame.
“This randomized, double-blind, placebo-controlled study is evaluating the efficacy and safety of two doses of SUVN-502 in moderate Alzheimer’s Disease patients who are taking both Aricept (donepezil) and Namenda (memantine). Study duration is 30 weeks. This is the first ever study to evaluate a triple combination therapy for moderate Alzheimer’s disease patients,” it said.
It further says that there is an urgent need for treatment options for patients with Alzheimer’s disease (AD) dementia since there are no new drugs discovered or developed from 2003 till now.
“We are very pleased to have completed last patient enrollment, surpassing our target enrollment of 537 patients by enrolling 563 patients in this Phase 2 study in moderate Alzheimer’s disease,” the company added.